The first time Avian influenza vaccine Trials have recently begun within the UK. This marks a milestone within the prevention of bird flu infection in humans.
The vaccine targets the H5N1 flu strain, which causes severe infections in bird populations worldwide. However, this strain of bird flu virus may also spread to humans in rare cases through direct contact with infected birds or poultry products.
The latest trial hopes to check the vaccine in people who find themselves most susceptible to getting bird flu. This includes people working within the poultry industry and folks over the age of 65.
Bird flu vaccine
This recent bird flu vaccine is an mRNA-based vaccine. This is identical technology that was utilized in a number of the COVID vaccines.
Messenger ribonucleic acid (mRNA) acts as a messenger between genes inside human cells and the microscopic factories that produce proteins. It carries a message from genes to those cellular factories to provide proteins with specific structures.
For example, it plays a job in producing mRNA. Enzymes which regulates our metabolism, Hemoglobin which carries oxygen to our tissues. Antibodies which protects us from infection.
Vaccines that use mRNA technology. Provides instructions to cellular protein production factories, telling them to provide certain proteins which can be normally present on the surface of a selected virus.
By doing so, these vaccines create a fake illness that’s less severe than the actual illness brought on by the virus. The immune system sees viruses or any of their parts (reminiscent of proteins) as intruders and tries to destroy them.
Once the fake disease is suppressed, the immune system will retain the memory of that individual virus. Thus, if an individual is exposed to the virus in the longer term, the immune system will respond in a short time and really strongly to destroy the virus and forestall the spread of the disease.
But for an mRNA vaccine to be effective, it must be efficiently transported from the positioning of administration to the blood. Immune cells. Like a letter that needs an envelope to get from sender to recipient, mRNA needs the appropriate carrier to get it to immune cells.
Like the Covid vaccine, this recent bird flu vaccine uses microscopic fatty spheres called Lipid nanoparticles to hold mRNA. These microscopic envelopes are around. 100-200 manometers in size (which is about 100,000 times smaller than a penny).
They are composed of a mixture of various fats (lipids) that form a microscopic sphere that incorporates the mRNA envelope. Different combos of lipids are used to customize the lipid nanoparticles to their carrying cargo. This maximizes the mRNA load they’ll carry and ensures that they don’t break down before delivering their cargo.
Before the introduction of mRNA-based vaccines and lipid nanoparticle technology, most influenza vaccines were produced by genetically modifying or chemically inactivating the virus. While this Live attenuated or inactivated virus While unable to induce a full-scale infection, they still stimulated an immune response.
But the method was expensive, time-consuming, and had mixed results. So it was reserved just for viruses that were on the World Health Organization’s priority list. Because bird flu has historically posed a low risk of infection to humans, there was no incentive to develop a vaccine for it.
nobeastsofierce/Shutterstock
But advances in mRNA technology and lipid nanoparticles now give us the tools to develop rapidly and cost-effective vaccines against a wide selection of viral infections – including low-priority diseases like bird flu.
Preventing the following pandemic
Although bird flu currently poses little threat to humans, it does exist. Potential to cause epidemic disease If its spread just isn’t controlled.
There are some. Main reasons For this in birds, H5N1 is amazingly virulent and recent strains evolve rapidly. It also has the power to remodel into various sorts of mammals – including humans.
Bird flu infection could cause severe illness that’s difficult to treat in vulnerable people. This includes people over the age of 65 and folks with weakened immune systems (reminiscent of cancer patients and folks who’ve had organ transplants). Therefore, if the virus managed to spread more easily between birds and humans, it could have serious consequences.
A vaccine trial is an lively effort to guard people from the potential of a future pandemic and to guard those that are at high risk of severe bird flu infection.
A bird flu vaccine that uses lipid nanoparticle technology has broader health applications beyond infectious diseases. One application is in developing cancer vaccines, where they might be used to treat existing cancer in patients.
I lead a research group on the University of Portsmouth working on developing recent mRNA-based vaccines against quite a lot of cancers, including breast, cervical and colorectal cancers, using lipid nanoparticles. The same technology is utilized in Moderna’s. mRNA vaccine against melanoma Which is currently under trial in UK.
The mRNA utilized in the cancer vaccine instructs a style of immune cell called a dendritic cell to provide the identical protein. expressed on tumor cells. Lipid nanoparticles act as envelopes to move this mRNA to those cells.
These cells produce and present cancer proteins to other members of the immune system, including T cells. As a result, the body will see the tumor cells as an intruder and can attempt to destroy them in the identical way it does with a virus.
Advances in mRNA synthesis and lipid nanoparticle technology herald a brand new era in vaccination. These recent technologies enable us to develop recent vaccines more quickly and customize them to attain higher effectiveness. This is of utmost importance to stop future epidemics.